Central nervous system (CNS) metastases are a common complication in patients with
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …

Purpose: Approximately one-third of patients with non–small cell lung cancer (NSCLC)
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …

Brain metastases are a common occurrence and a major cause of mortality in non-small-cell
lung cancer, with few systemic treatment options. Although targeting epidermal growth factor …

Survival and treatment options are limited for patients with brain metastases arising from non-
small cell lung cancer (NSCLC). We evaluated erlotinib and gefitinib as salvage treatments …

Abstract Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) …

Purpose Brain metastasis (BM) is a leading cause of death from non–small-cell lung cancer
(NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) …

8016 Background: Increasing numbers of EGFRm+ NSCLC patients with BM have been
reported, while effective treatment is lacking due to limited BBB penetration of currently …

Background Central nervous system (CNS) brain metastasis of advanced non-small cell
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …

Gefitinib is active and well tolerated in patients with advanced non-small cell lung cancer
(NSCLC); however, its role in patients with brain metastases has not been clearly defined …

Gefitinib is the first inhibitor of the epidermal growth factor receptor that has shown activity in
non–small-cell lung cancer (NSCLC), but its potential value in the treatment of central …